Accel Diagnostics is a medical technology company developing pScreen, a disposable protein test for the diagnosis, monitoring and management of a wide variety of medical conditions, including heart failure, cancer, osteoperosis, critical pregnancy, and infectious diseases. AccelDx's approach has the potential to be a serious disruptive element in the current diagnostic market, creating new market opportunities in the Home and Point-of-Care settings. AccelDx's platform technology leverages a patent-protected magnetic microfluidic system developed at Carnegie Mellon University. pScreen is a self-contained disposable blood test to measure the level of proteins (disease biomarkers) from a single droplet of body fluid, such as blood, saliva or urine, enabling patients and doctors to perform diagnostic tests that quantify biomarkers within minutes. It provides results that are comparable in accuracy to the ELISA and other laboratory-performed tests. By providing timely, affordable, and accurate medical test results, Accel enables physicians to manage their patients and reach disease resolution in a timely and cost-effective manner, reducing cost and preventing hospitalizations. It also enables patients to monitor and effectively manage the progression of their chronic diseases in the comfort of their home.
